Eloxx Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Eloxx Pharmaceuticals's estimated annual revenue is currently $3.3M per year.
- Eloxx Pharmaceuticals's estimated revenue per employee is $65,100
- Eloxx Pharmaceuticals's total funding is $52.5M.
- Eloxx Pharmaceuticals has 50 Employees.
- Eloxx Pharmaceuticals grew their employee count by 35% last year.
- Eloxx Pharmaceuticals currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.keywords:N/A
Number of Employees
Employee Growth %
|Amy Bombardier||Associate Director, Program Management|
|Greg Williams||Chief Operating Officer|
|Amy Daigle||Executive Assistant/Office Manager|
|Daniel Crawford||Principal Scientist, Pharmacology And Translational Sciences|
|Tristan Hu||Vice President, Biometrics|
|Robert Ward||Chairman And Chief Executive Officer|
|Sal Firicano||Senior Director, Information Technology|
|Neil Belloff||General Counsel|
|Rose Villandry||VP Human Resources|
|Kristie Kapinas||Director Of Advocacy And Alliances|
Eloxx Pharmaceuticals News
Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 ...
WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical ...
Eloxx Pharmaceuticals (OTCMKTS:ELOX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report ...
Eloxx Pharmaceuticals Executive Hires
|2018-06-19||Neil Belloff||EVP, General Counsel & Corporate Secretary||Article|
Eloxx Pharmaceuticals Acquisitions